Natalia M Martin Martin Orozco

Dr. Natalia M Martin Martin Orozco

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 January 2025 in npj Vaccines
Verified
Journal Article
Open access
PDF file
JLJun Liu
Jun Liu
LWLi Wang
Li Wang
AKAlexandra Kurtesi
Alexandra Kurtesi
PBPatrick Budylowski
Patrick Budylowski
KPKyle G. Potts
Kyle G. Potts
NONatalia M Martin Martin Orozco
Natalia M Martin Martin Orozco
Continuously emerging SARS-CoV-2 Omicron subvariants pose a threat thwarting the effectiveness of approved COVID-19 vaccines. Especially, the protection breadth and degree of these vaccines against antigenically distant Omicron subvariants is unclear. Here, we report the immunogenicity and efficacy of a bivalent mRNA vaccine, PTX-COVID19-M1.2 (M1.2), which encodes native spike proteins from Wuhan-Hu-1 (D614G) and Omicron BA.2.12.1, in mouse and hamster models. Both primary series and booster vaccination using M1.2 elicited potent and broad nAbs against Wuhan-Hu-1 (D614G) and some Omicron subvariants. Strong spike-specific T cell responses against Wuhan-Hu-1 and Omicron subvariants, including JN.1, were also induced. Vaccination with M1.2 protected animals from Wuhan-Hu-1 and multiple Omicron subvariants challenges. Interestingly, protection against XBB.1.5 lung infection did not correlate with nAb levels. These results indicate that M1.2 generated a broadly protective immune response against antigenically distant Omicron subvariants, and spike-specific T cells probably contributed to the breadth of the protection.

26 May 2023 in Scientific Reports
Verified
Journal Article
Open access
PDF file
NONatalia M Martin Martin Orozco
Natalia M Martin Martin Orozco
NVNoah Vale
Noah Vale
AMAlan Mihic
Alan Mihic
TATalya Amor
Talya Amor
LRLawrence Reiter
Lawrence Reiter
PPPiyush Patel
Piyush Patel
Access to vaccines against SARS-CoV-2 virus was limited in poor countries during the COVID-19 pandemic. Therefore, a low-cost mRNA vaccine, PTX-COVID19-B, was produced and evaluated in a Phase 1 trial. PTX-COVID19-B encodes Spike protein D614G variant without the proline-proline (986–987) mutation present in other COVID-19 vaccines. The aim of the study was to evaluate safety, tolerability, and immunogenicity of PTX-COVID19-B vaccine in healthy seronegative adults 18–64 years old. The trial design was observer-blinded, randomized, placebo-controlled, and tested ascending doses of 16-µg, 40-µg, or 100-µg in a total of 60 subjects who received two intramuscular doses, 4 weeks apart. Participants were monitored for solicited and unsolicited adverse events after vaccination and were provided with a Diary Card and thermometer to report any reactogenicity during the trial. Blood samples were collected on baseline, days 8, 28, 42, 90, and 180 for serum analysis of total IgG anti-receptor binding domain (RBD)/Spike titers by ELISA, and neutralizing antibody titers by pseudovirus assay. Titers in BAU/mL were reported as geometric mean and 95% CI per cohort. After vaccination, few solicited adverse events were observed and were mild to moderate and self-resolved within 48 h. The most common solicited local and systemic adverse event was pain at the injection site, and headache, respectively. Seroconversion was observed in all vaccinated participants, who showed high antibody titers against RBD, Spike, and neutralizing activity against the Wuhan strain. Neutralizing antibody titers were also detected against Alpha, Beta, and Delta variants of concerns in a dose dependent manner. All tested doses of PTX-COVID19-B were safe, well-tolerated, and provided a strong immunogenicity response. The 40-µg dose showed fewer adverse reactions than the 100-µg dose, and therefore was selected for a Phase 2 trial, which is currently ongoing.Clinical Trial Registration number: NCT04765436 (21/02/2021). (https://clinicaltrials.gov/ct2/show/NCT04765436).

3 December 2024 in PLOS ONE
Verified
Journal Article
Open access
PDF file
JHJacklyn R Hurst
Jacklyn R Hurst
MNMaedeh Naghibosadat
Maedeh Naghibosadat
PBPatrick Budowski
Patrick Budowski
JLJun Liu
Jun Liu
PSPhilip Samaan
Philip Samaan
RKRobert Kozak
Robert Kozak
The emergence of SARS-CoV-2 variants presents challenges to vaccine effectiveness, underlining the necessity for next-generation vaccines with multiple antigens beyond the spike protein. Here, we investigated a multiantigenic booster containing spike and a chimeric construct composed of nucleoprotein (N) and membrane (M) proteins, comparing its efficacy to a spike-only booster against Omicron BA.5 in K18-hACE2 mice. Initially, mice were primed and boosted with Beta (B.1.351) spike-only mRNA, showing strong spike-specific T cell responses and neutralizing antibodies, albeit with limited cross-neutralization to Omicron variants. Subsequently, a spike-NM multiantigenic vaccine was then examined as a second booster dose for protection in hACE2-transgenic mice. Mice receiving either homologous spike-only or heterologous spike-NM booster had nearly complete inhibition of infectious virus shedding in oral swabs and reduced viral burdens in both lung and nasal tissues following BA.5 challenge. Examination of lung pathology further revealed that both spike-only and spike-NM boosters provided comparable protection against inflammatory infiltrates and fibrosis. Moreover, the spike-NM booster demonstrated neutralization efficacy in a pseudovirus assay against Wuhan-Hu-1, Beta, and Omicron variants akin to the spike-only booster. These findings indicate that supplementing spike with additional SARS-CoV-2 targets in a booster immunization confers equivalent immunity and protection against Omicron BA.5. This work highlights a promising strategy for individuals previously vaccinated with spike-only vaccines, potentially offering enhanced protection against emerging coronaviruses.

10 May 2022 in medRxiv
Verified
Preprint
Open access
PDF file
NONatalia M Martin Martin Orozco
Natalia M Martin Martin Orozco
NVNoah Vale
Noah Vale
AMAlan Mihic
Alan Mihic
TATalya Amor
Talya Amor
LRLawrence Reiter
Lawrence Reiter
PPPiyush Patel
Piyush Patel
PTX-COVID19-B mRNA vaccine encodes for SARS-CoV-2 Spike protein G614 variant and lacks the proline-proline (986-987 position) mutation present in other COVID-19 vaccines. This Phase 1 observer-blinded, randomized, placebo-controlled, ascending dose study evaluated the safety, tolerability, and immunogenicity of two doses of PTX-COVID19-B vaccine in healthy seronegative adults. Participants received two intramuscular doses, 4 weeks apart, of 16-μg, 40-μg, or 100-μg PTX-COVID19-B. Adverse events were generally mild to moderate, self-resolving, and transient. The most common solicited local and systemic adverse event was pain at the injection site and headache, respectively. After the first immunization, all participants seroconverted, producing high titers of anti-receptor-binding-domain, anti-Spike, and neutralizing antibodies, including neutralizing antibodies against the ancestral viral strain and the Alpha, Beta, and Delta variants of concern, in a dose-dependent way, further increasing over 10-20 times after the second dose. All tested doses of PTX-COVID19-B were safe, well-tolerated, and provided a strong immunogenicity response. The 40-μg dose showed fewer adverse reactions than the 100-μg dose, supporting further investigation of the 40-μg dose. Clinical Trial Registration ClinicalTrials.gov identifier: NCT04765436 (https://clinicaltrials.gov/ct2/show/NCT04765436)

28 August 2026 in Molecular Therapy Nucleic Acids
Verified
Journal Article
Open access
MGMatthew J. Gold
Matthew J. Gold
DMDouglas G. Millar
Douglas G. Millar
JLJun Liu
Jun Liu
HMHaritha Menon
Haritha Menon
YKYury Karpov
Yury Karpov
NONatalia M Martin Martin Orozco
Natalia M Martin Martin Orozco

23 April 2024 in Research Square
Verified
Preprint
Open access
PDF file
JLJun Liu
Jun Liu
LWLi Wang
Li Wang
AKAlexandra Kurtesi
Alexandra Kurtesi
PBPatrick Budylowski
Patrick Budylowski
KPKyle Potts
Kyle Potts
NONatalia M Martin Martin Orozco
Natalia M Martin Martin Orozco
The continuous emergence of SARS-CoV-2 Omicron subvariants poses a serious threat thwarting the effectiveness of currently approved COVID-19 vaccines, demanding a vaccine that can provide broad protection against these subvariants. Although bivalent vaccines containing Omicron subvariant spikes have been shown to elicit high neutralizing antibodies (nAbs) and afford protection against homologous or antigenically close Omicron subvariants, the breadth and degree of the protection provided by the bivalent vaccines against antigenically distant Omicron subvariants is unclear. Here, we report the immunogenicity and efficacy of a bivalent mRNA vaccine, PTX-COVID19-M1.2 (M1.2), which encodes native spike proteins from Wuhan-Hu-1 (D614G) and Omicron BA.2.12.1, in mouse and hamster models. Both primary series and booster vaccination using M1.2 elicited potent and broad nAbs against Wuhan-Hu-1 (D614G) and Omicron subvariants, including BA.1, BA.2, BA.2.12.1, and BA.4/BA.5. Strong spike-specific T cell responses against Wuhan-Hu-1 and Omicron subvariants were also induced. In contrast, monovalent BA.2.12.1 spike-based mRNA vaccine elicited potent but narrower immune responses. Vaccination with M1.2 protected animals from Wuhan-Hu-1 and BA.1, BA.2, BA.5, and XBB.1.5 challenges. Interestingly, protection against XBB.1.5 lung infection did not correlate with nAb levels. These results indicate that M1.2 can generate a broadly protective immune response against multiple Omicron subvariants, including antigenically distant subvariants, and spike-specific T cells probably contribute to the breadth of the protection. Our findings have potential implications for designing COVID-19 booster vaccination strategies.